The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or …

The cancer vaccine roller coaster | Nature Biotechnology Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain …

Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein-
4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have increased …

A simple model of three competing cell populations (host, immune and tumor cells) is
revisited by using a topological analysis and computing observability coefficients. Our aim is …

HLA-E is a non-classical MHC molecule whose expression by tumour cells has been
recently reported in several human cancer types. We studied HLA-E expression in colorectal …

The evolutionarily selected tissue-protecting mechanisms are likely to be triggered by an
event of universal significance for all surrounding cells. Such an event could be damage to …

Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) plays a key role in restraining the
adaptive immune response of T-cells towards a variety of antigens including tumor …

Although much evidence has been gathered demonstrating that immune effectors can play a
significant role in controlling tumor growth under natural conditions or in response to …

Cancers escape immune surveillance through the manipulation of the host's immune
system. Sequestration of dendritic cells (DCs) within tumor tissues and the subsequent …

Observations from different research frontiers—epidemiological data, case studies on
spontaneous regressions from cancer, clinical studies, tumor immunology—indicate that …